RegeneRx Biopharmaceuticals, Inc.
3 Bethesda Metro Center, Suite 630
Bethesda
Maryland
20814
United States
Tel: 301-280-1992
Fax: 301-280-1996
Website: http://www.regenerx.com/
Email: info@regenerx.com
329 articles about RegeneRx Biopharmaceuticals, Inc.
-
RegeneRx Advisory on ARISE-3 Dry Eye Trial
6/2/2020
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the revised schedule for completion of the ARISE-3 dry eye clinical trial, http://www.regenerx.com/2020-06-02-June-2-2020-Advi
-
RegeneRx Advisory on Reclassification of Thymosin Beta 4 from Drug to Biologic
5/27/2020
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the FDA's reclassification of Thymosin beta 4 (Tβ4) from a drug to a biologic,
-
RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259
5/14/2020
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration announced efficacy results of its Phase 3 clinical trial in patients with neurotrophic keratopathy.
-
ReGenTree Announces Efficacy Results of the Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259
5/14/2020
ReGenTree, LLC, a U.S. joint venture company owned by GtreeBNT Co., Ltd, and RegeneRx Biopharmaceuticals, Inc., announced the results of a randomized, double masked, placebo-controlled Phase 3 clinical trial using RGN-259 for the treatment of neurotrophic keratopathy.
-
RegeneRx Issues Advisory on ARISE-3 Dry Eye Trial
4/20/2020
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial. To access the advisory, go to the following link: http://www.regenerx.com/2020-04-20-Ap
-
New Publication Describes Mechanism of Action for Tβ4 in Corneal Wound Healing and Regeneration
4/2/2020
RegeneRx Biopharmaceuticals, Inc. announced the publication of a new scientific study demonstrating a mechanism of action of thymosin beta 4 on human corneal epithelial cell migration and the downstream signaling pathways.
-
RegeneRx Issues Advisory on Dry Eye Trial Amid COVID-19 Virus
3/18/2020
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial. To access the advisory, go to the following link: http://www.regenerx.com/2020-03-18-Ma
-
RegeneRx Partner Receives Canadian Patent For Treatment of Peripheral Neuropathy
2/13/2020
ROCKVILLE, Md. , Feb. 13, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the Canadian Patent Office has issued a new patent to the Henry Ford Health System (HFHS) for treating patients with peripheral neuro
-
RegeneRx Partner Updates on Phase 3 Dry Eye Trial
2/3/2020
Over 350 Patients Enrolled in 3rd Phase 3 Clinical Trial
-
RegeneRx Publishes Annual Letter to Shareholders - Jan. 22, 2020
1/22/2020
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, published its annual letter to stockholders on the Company's website at www.regenerx.com.
-
RegeneRx Partner Receives Patent for Reducing Diabetic-Induced Vascular Dysfunction in Korea
1/21/2020
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, reported today that the Korean Intellectual Property Office has issued a new patent to the Henry Ford Health System (HFHS) for a Thymosin beta 4 (Tβ4) composition for reducing diabetic-induced vascular dysfunction
-
RegeneRx's Tβ4 Significantly Reduces Damage in Ischemic Acute Kidney Injury Model
11/18/2019
In this study, researchers reported that administration of Tβ4 to animals with induced kidney injury significantly reduced ischemic acute kidney injury.
-
RegeneRx's Tβ4 Promotes Autophagy and Repair in Chronic Granulomatous Disease Model
11/14/2019
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), today announced the publication of a new scientific study demonstrating how Thymosin beta 4 (Tβ4) promotes the body's ability to clean out damaged cells in order to regenerate newer, healthier cells (autophagy) and repair damage in chronic granulomatous disease (CGD).
-
RegeneRx JV Partner Updates on Strategic Dry Eye Discussions
10/16/2019
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, released a summary of its U.S. joint venture partner, GtreeBNT's, recent attendance at the American Academy of Ophthalmology meeting (AAO) in San Francisco, California.
-
RegeneRx Partner Updates on ARISE-3 Clinical Trial
9/30/2019
Enrollment on Target for Completion of Phase 3 Dry Eye Trial in Q2 2020
-
RegeneRx to Present at Fall Investor Summit on September 17
9/10/2019
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at the Fall Investor Summit on September 17, 2019, at 8:30 a.m. ET in New York City.
-
RegeneRx Modifies September Conference Schedule
9/4/2019
The Company will not be presenting at the Rodman & Renshaw Investment Conference on September 8-10 as was previously announced.
-
First Patient Enrolled in RGN-137 Trial for Epidermolysis Bullosa Experiences Complete Wound Healing
8/5/2019
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), today confirmed that the first patient enrolled in a single blinded, phase 2 clinical trial in patients with epidermolysis bullosa (EB) has positively responded to RGN-137, the Company's novel topically-administered drug candidate.
-
RegeneRx's RGN-137 for Epidermolysis Bullosa Subject of New Article in Seeking Alpha Investor Site
7/29/2019
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that RGN-137, the Company's wound healing product candidate currently the subject of a U.S. clinical trial,
-
RegeneRx to Present at the Rodman & Renshaw and the Fall Investor Summit Conferences in September 2019
7/16/2019
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at the Rodman & Renshaw 21st Annual Global Investment Conference on September 8-10, 2019